Thrombolysis in acute myocardial infarction.
Reperfusion of ischaemic myocardium with thrombolytic agents during the early stages of acute myocardial infarction reduces the mortality rate and can limit infarct size with associated sparing of left ventricular function. Effective and safe regimens are now available and in the absence of contraindications thrombolysis should now form part of the standard management acute myocardial infarction.
Holmberg
S R
SR
Royal Sussex County Hospital, Brighton.
D016255:Anistreplase / Q000494:pharmacology / Q000627:therapeutic use; D002985:Clinical Protocols; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013300:Streptokinase / Q000494:pharmacology / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use
D011994:Recombinant Proteins; D016255:Anistreplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator